https://www.selleckchem.com/btk.html
Nephropathy with Atrasentan (SONAR), NCT01858532. Atrasentan reduced the relative risk of the primary kidney outcome consistently across baseline UACR and eGFR subgroups. The absolute risk reduction was greater among patients in the lowest eGFR and highest albuminuria category who were at highest baseline risk. Conversely, the relative and absolute risks of heart failure hospitalization were similar across baseline UACR and eGFR subgroups.Clinical Trial registry name and registration number Study of Diabetic Nephropathy with Atrasentan (SONAR), NCT0
Like
Comment
Share
